The effectiveness of intravenous thrombolysis in acute ischemic stroke is time dependent. The effects are likely to be highest if the time from symptom onset to treatment is within 60 minutes, termed the golden hour.
T ime to treatment with tissue plasminogen activator (tPA) is crucial to outcomes among patients with acute ischemic stroke.
1,2 Numerous attempts have been made to reduce the time from symptom onset to treatment (OTT). 3, 4 However, many centers struggle to keep the time from arrival at the hospital to initiation of tPA (door-to-needle time) shorter than 60 minutes. 5, 6 When prehospital times are added to inhospital delays, an OTT within the first 60 minutes of symptom onset, termed the golden hour, seems out of reach for most patients. In fact, most patients undergoing routine care for stroke receive treatment rather late. In the Safe Implementation of Thrombolysis-Stroke Monitoring Study (SITS-MOST) registry, 7 10 .6% of 6483 patients were treated within 90 minutes and only 1.4% within 60 minutes. The median OTT in the SITS-International Stroke Thrombolysis Register 8 was 145 (interquartile range [IQR] , 115-170) minutes. Structured approaches have been successful in increasing thrombolysis rates and shortening door-to-needle times. [9] [10] [11] Centers with greater numbers of tPA treatments per year tend to have shorter doorto-needle times compared with smaller centers. 5 However, some of the centers with shortened door-to-needle times still have long prehospital times. 9, 12 A forceful approach to shorten the OTT is prehospital thrombolysis in emergency vehicles equipped with a computed tomographic scanner and a point-of-care laboratory. [13] [14] [15] A reduced time from the emergency call to treatment after deployment of such an ambulance compared with regular care was observed in the Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) study. 15 We used data from the PHANTOM-S study to evaluate the rate and effectiveness of golden hour thrombolysis.
Methods
The study was approved by the Charité Ethics Committee and conducted in accordance with published protocol. Written informed consent was obtained from patients able to communicate and waived for those unable to provide consent, as described in detail previously. 15 Methodologic details of the PHANTOM-S study have been described previously. 16, 17 In brief, an ambulance, the stroke emergency mobile unit (STEMO), was equipped with a computed tomographic scanner and point-of-care laboratory. The unit was staffed with a neurologist trained in emergency medicine (including M.E., A.K., M.W., M.R., B.W., C.W., and J.W.), a paramedic, and a radiology technician. A neuroradiologist was on call to evaluate images acquired on board the STEMO via a teleradiology connection. We evaluated the effects of the STEMO implementation prospectively by comparing weeks with and without STEMO availability. The STEMO was deployed when the dispatchers suspected an acute stroke during emergency calls. If STEMO was not available (during control weeks, while the unit was in operation, or during maintenance), patients received conventional care. For this post hoc analysis based on data from the PHANTOM-S study, we used the same consecutive patients and baseline variables as in the original study. 15 Stroke severity at baseline was assessed according to the National Institutes of Health Stroke Scale (NIHSS). 18 In addition, we calculated the proportion of patients treated in 1-hour intervals. The OTT intervals were dichotomized as 60 minutes or less (the golden hour) or longer than 60 minutes. Only 1 STEMO was available within a catchment area of more than 1 million inhabitants. Therefore, the STEMO could not be deployed for all suspected strokes during STEMO weeks when the STEMO was occupied with another emergency. In contrast to the original study, 15 we did not compare STEMO weeks with control weeks in the data presented here. Instead we compared tPA treatments occurring after STEMO deployment with tPA treatments during conventional care. Conventional care included tPA treatments during control weeks and tPA treatments during STEMO weeks without STEMO deployment ( Figure 1) . In a second step, we compared stroke patients who received golden hour thrombolysis with stroke patients who received tPA more than 60 minutes after symptom onset, independent of STEMO deployment or conventional care. Patients with stroke mimics who received tPA were not included in this evaluation of treatment effects. We calculated unadjusted outcomes for 7-and 90-day mortality, secondary intracerebral hemorrhage, and discharge home among patients with an OTT within 60 minutes compared with those with an OTT longer than 60 minutes. We then performed analyses to achieve the adjusted probability of each outcome.
With relatively few patients who experienced a secondary hemorrhage (n = 29) or died within 7 days (n = 24), we had to restrict the adjustment to 2 variables and adjusted for age (in decades) and stroke severity (NIHSS score per point). For the outcomes of death within 90 days (n = 75) and discharge home (n = 239), we adjusted for age (in decades), sex, atrial fibrillation, and NIHSS score categories according to the Third International Stroke Trial (NIHSS scores, 0-5, 6-10, 11-15, 16-20, and ≥21). 19 We considered P < .05 to be a statistically significant difference.
Results

STEMO Deployment vs Conventional Care
All data of this post hoc analysis presented herein were recalculated on the basis of the PHANTOM-S data set. During the 21 months from May 1, 2011, through January 31, 2013, there were 3213 emergency calls for suspected stroke during STEMO weeks and 2969 during control weeks ( Figure 1 
Golden Hour Thrombolysis vs Later Thrombolysis
Median OTT was 50.0 (IQR, 43-55) minutes in golden hour thrombolysis vs 105.0 (IQR, 85-155) minutes in all other thrombolysis (P < .001). In patients who received golden hour thrombolysis, median NIHSS score was higher than that in patients who received tPA more than 60 minutes after symptom onset (12 [IQR, 5-18] vs 7 [IQR, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] ; P = .006) (additional baseline characteristics are given in Table 1 ). In unadjusted univariate analysis of the outcomes mortality within 7 and 90 days, discharge home, and hemorrhagic complications, we detected no significant differences between golden hour thrombolysis and later thrombolysis ( 
Discussion
Prehospital stroke treatment within the STEMO concept increased the number of tPA treatments within the golden hour almost 10-fold. Golden hour thrombolysis was associated with improved patient outcomes regarding the discharge destina- 
Conventional care
The major difference in proportions between the group treated after deployment of the stroke emergency mobile unit (STEMO) and the group treated with conventional care can be observed within the first 60 minutes of symptom onset.
tion from acute in-hospital care. We observed no increased risk for hemorrhagic complications or mortality in patients undergoing golden hour thrombolysis. Deployment of STEMO led to a significant proportion of patients with extremely early treatment, even in a setting with already short median doorto-needle times and OTT in the control group (36.0 [IQR, 28-51] and 105.0 [IQR, 81-145] minutes, respectively). Our results regarding safety and discharge status after golden hour thrombolysis are in line with previous analyses of the association of improved outcomes with shorter OTT. 1, 2, 20 Thrombolytic treatment within the first 60 minutes has rarely been reported. Only 4 of 3670 patients with time to treatment within 1 hour were included in the randomized stroke thrombolysis trials according to the last pooled data set. 21 Nevertheless, the term golden hour has become used frequently in acute stroke management. 3, 4 The rapid death of brain cells after blockage of cerebral blood supply makes immediate treatment to dissolve or remove clots indispensable. Starting treatment at the scene has become a realistic scenario. The high percentage of early treatments also raises hopes for other potentially effective treatments, such as neuroprotective substances.
This study has limitations. The significance and generalizability of the results presented here are limited owing to the nature of a post hoc analysis. These explorative results need to be confirmed using a prospective approach. The PHANTOM-S study was originally designed to detect a reduced time from the emergency call to treatment and was not powered to detect functional outcome differences. The use of discharge destination from acute in-hospital care can only be interpreted as a surrogate variable. The higher frequency of patients discharged home was only shown for patients treated within the golden hour and not for the entire cohort of patients who received STEMO care. Randomization was not performed at the patient level, but weeks were allocated to usual stroke care or additional STEMO availability. Finally, bias of spontaneous recovery remains a possibility when comparing extremely early vs late thrombolysis. The question of generalizability of the prehospital thrombolysis concept warrants further studies. Not all countries are accustomed to emergency physicians in the field, which may be required for adaptation of the STEMO concept. The OTT found in our study after STEMO deployment (median OTT, 80.5 minutes) and during conventional care (median OTT, 105.0 minutes) were much shorter than in published stroke thrombolysis registries (median OTTs, 144 minutes in Saver et al 2 and 140 minutes in Wahlgren et al 7 ) or even in best-practice hospital systems (median OTT, 119 minutes for Meretoja et al 9 ).
Apart from a selection bias by restriction to patients with ambulance care, this difference may be explained at least in part by a well-established metropolitan stroke care system with trained dispatchers and paramedics, short distances to stroke units, and rather optimized in-hospital procedures. During the study period, the dispatchers identified patients with typical stroke symptoms during the emergency call and notified the emergency medical services, which may have raised awareness of the entire rescue chain.
Conclusions
The concept of prehospital thrombolysis is still relatively new, and experience is limited to few groups. Further improvements in time reduction may be expected with growing routine. After analyzing data from the Get With the Guidelines Stroke Program, Saver and colleagues 2 concluded that every effort should be made to accelerate thrombolytic treatment in patients with stroke. Our post hoc analysis supports this timeis-brain concept. Golden hour thrombolysis was associated with better short-term outcomes. 
